Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Given recent price action, a buy-the-dip scenario could be on the cards. Leverage the power ... The more I dig into Eli Lilly’s business, the more confident I become. Beyond the GLP-1 hype ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...

Eli Lilly, BCE, Suncor, Canada Goose ... “To put it bluntly, we’re not in the business of building fibre for Telus’s benefit, and that’s what the CRTC policy that’s in place right ...

Shares in the automaker were lower in premarket trading after the automaker said deep losses in its electric-car business would [weigh on profitability in 2025]( ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Hanwha Asset Management noted on the 7th that even when investing in the ‘PLUS High Dividend’ exchange-traded fund (ETF) that ...

Rocketing demand, legal disputes, and the future of weight loss were all spurred by a new class of anti-obesity medications.

Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.